title: Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?
abstract: Recent advances in tumor genetics and drug development have led to the generation of a wealth of anti-cancer-targeted therapies. These drugs aim at targeting a particular vulnerability in the tumor generated in most cases as a result of dependence on an oncogene and/or loss of a tumor suppressor. Genes in the phosphoinositide 3-kinase (PI3K)/AKT pathway are the most frequently altered in human cancers. Aberrant activation of the PI3K/AKT pathway has been shown to confer resistance to HER2-targeted therapies. Several drugs targeting PI3K/ATK have been developed and are currently in clinical trials in different phases of clinical development, alone or in combination. The impact of mutations in the phosphoinositide 3-kinase (PI3K)/AKT pathway in HER2-amplified breast cancers will be the focus of this review.
authors.affiliation: Department of Medicine, Breast Cancer Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, USA; Division of Hematology/Oncology, Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, 2220 Pierce Avenue, 777 PRB, Nashville, TN 37232-6307, USA.
authors.forename: Ingrid A
authors.initials: IA
authors.lastname: Mayer
keywords: Breast cancer; Clinical trials; Mammalian target of rapamycin (mTOR); Mutation; Pathway inhibitors; Phosphoinositide 3-kinase (PI3K)/AKT